As lung transplants become more common, clinicians should be aware of post-transplant dermatologic complications including melanoma.
The 31-GEP identifies low-risk patients most likely to benefit from intensive surveillance and adjuvant therapy.
Dr. Funchain applies practical translation of genomic data to clinical precision oncology, melanoma survivorship and predictors of clinical outcomes and adverse events related to immunotherapy.
Investigating tumor mutational burden, specific driver mutations, immune-related RNA expression data and various clinicopathologic features from 479 tumors to find correlations with clinical characteristics and outcomes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic experts will address important advances in the treatment of melanoma in this complimentary one-day symposium.
For many years, researchers, patients and clinicians saw little progress in the development of new medications for advanced melanoma. But recent, unprecedented advances in drug development have led to the approval of effective new drugs to treat advanced disease.
Starting immunotherapy first-line for patients with melanoma containing BRAF mutations, followed by BRAF + MEK inhibitors, was associated with longer survival and lower costs compared with prescribing inhibitors first.
People with a higher incidence of cancer — multiple melanomas, melanoma and additional cancers or a family history of melanomas and other malignancies — can carry a higher risk for breast, pros-tate, brain and other cancers.
Participation in the registry will bolster the understanding of melanoma heritability and genetic underpinnings as well as offer patients the option to learn and share test results.
Treatment delay negatively impacts overall survival for patients with stage I melanoma.